PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Dr. Karen Smith, MD, PhD, MBA, LLM, as interim Chief Medical Officer (CMO), effective May 10 ...

today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. “Karen and Luke’s vast experience and proven leadership in the ...

today announced Dr. Karen Smith, MD, PhD, MBA, LLM as interim Chief Medical Officer (“CMO”). Dr. Smith replaces Dr. Claudio Dansky Ullmann, who will be leaving the Company effective May 10 ...

Nimacimab is a first-in-class humanized monoclonal antibody that acts as a negative allosteric modulator to inhibit CB1 signaling in the periphery. Inhibition of CB1 has shown anti-fibrotic, anti ...

Dr Karen Smith is an experienced pharmaceutical expert who has overseen ... AstraZeneca and Bristol-Myers Squibb. Dr Smith earned an MD from the University of Warwick (UK), PhD in Molecular Oncology ...

today announced Dr. Karen Smith, MD, PhD, MBA, LLM as interim Chief Medical Officer (“CMO”). Dr. Smith replaces Dr. Claudio Dansky Ullmann, who will be leaving the Company effective May 10 ...

04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD ...

Karen Smith, MD, PhD, MBA, LLM , has served as a C-suite biotech industry consultant and pharmaceutical executive, member of the board and clinical and scientific advisor during her 20-year career.